Codexis Senior Vice President of R&D Dr. Jim Lalonde Announces Plan to Resign
April 05 2019 - 4:05PM
Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering
company, announces that Jim Lalonde, Ph.D., Senior Vice President
of Research and Development, will resign effective May 31, 2019 to
pursue other interests.
“Jim has played an integral role over many years with the
Codexis team refining and applying our CodeEvolver® protein
engineering platform. We thank him for his many contributions to
the success of our company and wish him well in his future
endeavors,” said John Nicols, Codexis President and Chief Executive
Officer. “With a deeply experienced and long-tenured leadership
team under Jim, we have full confidence in the seamless continuity
of our R&D function. Succession plans are in motion to
ensure that Codexis is setup for the next chapter of technology
advancements and stepout growth applying the CodeEvolver® protein
engineering platform.”
“I am extremely grateful to all of the past and present
scientists at Codexis. It has been a privilege to collaborate with
such talented professionals, and to have helped drive the
CodeEvolver® protein engineering platform to deliver sustainable
solutions to a growing number of industries,” said Dr. Lalonde. “I
am very proud of the R&D team assembled at Codexis, and am
confident all ongoing and planned programs are in capable
hands.”
About Codexis, Inc.
Codexis is a leading protein engineering company that applies
its proprietary CodeEvolver® technology to develop proteins for a
variety of applications, including as biocatalysts for the
commercial manufacture of pharmaceuticals, fine chemicals and
industrial enzymes, and enzymes as biotherapeutics and for use in
molecular diagnostics. Codexis’ proven technology enables
improvements in protein performance, meeting customer needs for
rapid, cost-effective and sustainable manufacturing in multiple
commercial-scale implementations of biocatalytic processes. For
more information, see www.codexis.com
Forward-Looking Statements
To the extent that statements contained in this press release
are not descriptions of historical facts regarding Codexis, they
are forward-looking statements reflecting the current beliefs and
expectations of management made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
You should not place undue reliance on these forward-looking
statements because they involve known and unknown risks,
uncertainties and other factors that are, in some cases, beyond
Codexis’ control and that could materially affect actual results.
Additional information about factors that could materially affect
actual results can be found in Codexis’ Annual Report on Form 10-K
filed with the Securities and Exchange Commission (“SEC”) on March
9, 2019 under the caption “Risk Factors” and in Codexis’ other
periodic reports filed with the SEC. Codexis expressly
disclaims any intent or obligation to update these forward-looking
statements, except as required by law..
Investors LHA Investor RelationsJody Cain,
310-691-7100 jcain@lhai.com
Codexis (NASDAQ:CDXS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Codexis (NASDAQ:CDXS)
Historical Stock Chart
From Apr 2023 to Apr 2024